CoChat
Sign Up
Cited by 344Psychedelics and Drug StudiesForensic Toxicology and Drug AnalysisSchizophrenia research and treatment

The DOI matches its Crossref record; 133 of the 137 references it cites were found in a registry or an index.

Psychiatry & the psychedelic drugs. Past, present & future

Open access
Rucker, James J.H., Iliff, Jonathan, Nutt, David J.·2018·Neuropharmacology
DOI 10.1016/j.neuropharm.2017.12.040
Open this paper in CoChat — free accountOpen PDF

Abstract

The classical psychedelic drugs, including psilocybin, lysergic acid diethylamide and mescaline, were used extensively in psychiatry before they were placed in Schedule I of the UN Convention on Drugs in 1967. Experimentation and clinical trials undertaken prior to legal sanction suggest that they are not helpful for those with established psychotic disorders and should be avoided in those liable to develop them. However, those with so-called 'psychoneurotic' disorders sometimes benefited considerably from their tendency to 'loosen' otherwise fixed, maladaptive patterns of cognition and behaviour, particularly when given in a supportive, therapeutic setting. Pre-prohibition studies in this area were sub-optimal, although a recent systematic review in unipolar mood disorder and a meta-analysis in alcoholism have both suggested efficacy. The incidence of serious adverse events appears to be low. Since 2006, there have been several pilot trials and randomised controlled trials using psychedelics (mostly psilocybin) in various non-psychotic psychiatric disorders. These have provided encouraging results that provide initial evidence of safety and efficacy, however the regulatory and legal hurdles to licensing psychedelics as medicines are formidable. This paper summarises clinical trials using psychedelics pre and post prohibition, discusses the methodological challenges of performing good quality trials in this area and considers a strategic approach to the legal and regulatory barriers to licensing psychedelics as a treatment in mainstream psychiatry. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2017.12.040

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 137 references

Research works printed but not linked: 2

  1. Prentiss, 1895, Anhalonium lewinii (mescal buttons), Ther. Gaz., 11, 577
  2. Savage, 1967, The effectiveness of psychedelic (LSD) therapy: a preliminary report, Br. J. Soc. Psychol., 2, 59

Cited by

Sorted by citations

Items 301–344 of 344

Related

See all

Metadata

Authors
Rucker, J. J. H., Iliff, J., & Nutt, D. J.
Affiliations
  • King's College London (GB)
  • University College London (GB)
  • Imperial College London (GB)
Corresponding author
Rucker, James J.H.
ORCID
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2018-11
Volume
142
Pages
200-218
ISSN
0028-3908 (ISSN-L)
DOI
10.1016/j.neuropharm.2017.12.040
OpenAlex
W2781316183
Cited by
343
References
137
Citations by year
2026: 38 · 2025: 40 · 2024: 59 · 2023: 49 · 2022: 50 · 2021: 50 · 2020: 36 · 2019: 14 · 2018: 7
FWCI
2.38
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropharmacology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion, cc-by-nc-nd)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • National Institute for Health Research (NIHR) Biomedical Research Centre at South London
  • Maudsley NHS Foundation Trust
  • King's College London
  • UK Medical Research Council (MR/J00460X/1)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
psychedelics, psilocybin, lysergic acid diethylamide, mescaline, psychedelic-assisted psychotherapy, unipolar mood disorders, alcoholism, adverse events, psychosis risk
MeSH terms
Animals, Mental Disorders, Clinical Trials as Topic, Hallucinogens, Humans, Psychiatry

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review